Taking A Bold Path To Improve Fibrosis Prognosis
Agomab Is Targeting Two Growth Factor Pathways Which Could Help To Modify Disease Outcomes
Tim Knotnerus is empowering Agomab’s team to investigate the potential of growth factor pathways across four different fibrotic indications.
You may also be interested in...
After nearly two difficult years for Nichi-Iko Pharmaceutical, the firm has announced at it will be acquired by a private equity fund and delisted from the Toyko Stock Exchange in 2023 and its CEO will step down from his post.
Advanz has identified three key spaces in which it is seeking to generate value: innovative assets, M&A and existing commercial infrastructure.
Sun Pharmaceuticals continues to dominate the Indian pharmaceutical space while its R&D costs are set to rise.